The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

To understand what drives disease progression in tissues, scientists need more than just a snapshot of cells in ...

Panelists discuss how chronic graft-vs-host disease (cGVHD) results from complex biological mechanisms involving inflammation, loss of peripheral tolerance, and fibrotic pathways affecting multiple ...

AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer diagnostics ...

The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...